Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01007110 · ClinicalTrials.gov registry record · Phase 3
Effects of Docosahexaenoic Acid (DHA) on Fetal Cardiac Outcomes
A Phase 3 study, sponsored by University of Kansas.
- Completed
- Registry status
- Phase 3
- Development phase
- 67
- Enrollment target
NCT01007110 is a Phase 3 study that has completed, run by University of Kansas. The registered enrollment target is 67 participants.
The verdict
NCT01007110, a Phase 3 study, has completed, sponsored by University of Kansas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 67 participants
- Enrollment target
Study Summary
DHA, a type of fatty acid, is important in early development, both in terms of reproductive physiology of gestation and in postnatal behavioral and cognitive function. In adults, DHA has been shown to lower triglycerides and is important to cardiovascular health and autonomic control, lowering heart rate and blood pressure and increasing heart variability. Little is known about how fatty acids impact cardiac control in infants, children or the fetus. Our hypothesis is that maternal DHA supplementation (600 mg/day) will lower fetal HR and increase fetal HRV.
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT DHA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2009-05 |
| Est. Completion | 2011-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01007110
The ClinicalTrials.gov registry entry for NCT01007110 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01007110 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01007110 about?
NCT01007110 is a clinical study titled "Effects of Docosahexaenoic Acid (DHA) on Fetal Cardiac Outcomes". DHA, a type of fatty acid, is important in early development, both in terms of reproductive physiology of gestation and in postnatal behavioral and cognitive function. In adults, DHA has been shown to lower triglycerides and is important to cardiovascular health and autonomic control, lowering heart...
What is the current status of trial NCT01007110?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 67 participants. The study started on 2009-05. Estimated completion is 2011-07.
What interventions are being tested in trial NCT01007110?
The interventions under investigation include: Placebo (OTHER), DHA (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01007110?
This trial is sponsored by University of Kansas, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.